Carlisle B - Search Results

1

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.

Hutchinson N, Carlisle B, Doussau A, Bosan R, Gumnit E, MacPherson A, Fergusson DA, Kimmelman J. Hutchinson N, et al. Among authors: carlisle b. JAMA Netw Open. 2021 May 3;4(5):e2110456. doi: 10.1001/jamanetworkopen.2021.10456. JAMA Netw Open. 2021. PMID: 34003270 Free PMC article.

2

Research ethics. Rethinking research ethics: the case of postmarketing trials.

London AJ, Kimmelman J, Carlisle B. London AJ, et al. Among authors: carlisle b. Science. 2012 May 4;336(6081):544-5. doi: 10.1126/science.1216086. Science. 2012. PMID: 22556237 Free PMC article.

3

Late, never or non-existent: the inaccessibility of preclinical evidence for new drugs.

Federico CA, Carlisle B, Kimmelman J, Fergusson DA. Federico CA, et al. Among authors: carlisle b. Br J Pharmacol. 2014 Sep;171(18):4247-54. doi: 10.1111/bph.12771. Epub 2014 Jul 2. Br J Pharmacol. 2014. PMID: 24825131 Free PMC article.

4

Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.

Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Carlisle B, et al. Clin Trials. 2015 Feb;12(1):77-83. doi: 10.1177/1740774514558307. Epub 2014 Dec 4. Clin Trials. 2015. PMID: 25475878 Free PMC article.

5

Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials.

Hakala A, Kimmelman J, Carlisle B, Freeman G, Fergusson D. Hakala A, et al. Among authors: carlisle b. BMJ. 2015 Mar 9;350:h1116. doi: 10.1136/bmj.h1116. BMJ. 2015. PMID: 25752879 Free article.

6

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J. Carlisle B, et al. J Natl Cancer Inst. 2015 Nov 7;108(1):djv292. doi: 10.1093/jnci/djv292. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26547927 Free PMC article. Review.

7

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.

Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Mattina J, et al. Among authors: carlisle b. PLoS Biol. 2017 Feb 3;15(2):e2000487. doi: 10.1371/journal.pbio.2000487. eCollection 2017 Feb. PLoS Biol. 2017. PMID: 28158308 Free PMC article. Review.

8

Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections.

Kimmelman J, Carlisle B, Gönen M. Kimmelman J, et al. Among authors: carlisle b. JAMA. 2017 Sep 19;318(11):1003-1004. doi: 10.1001/jama.2017.11502. JAMA. 2017. PMID: 28837722 No abstract available.

9

Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.

Carlisle B, Federico CA, Kimmelman J. Carlisle B, et al. BMJ. 2018 Mar 20;360:k959. doi: 10.1136/bmj.k959. BMJ. 2018. PMID: 29559429 No abstract available.

10

How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?

Pratte M, Ganeshamoorthy S, Carlisle B, Kimmelman J. Pratte M, et al. Among authors: carlisle b. Int J Cancer. 2019 Dec 15;145(12):3370-3375. doi: 10.1002/ijc.32405. Epub 2019 May 29. Int J Cancer. 2019. PMID: 31087646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters